COMPARATIVE EFFICACY AND SAFETY STUDY OF FINASTERIDE VERSUS DUTASTERIDE, IN ADDITION TO TADALAFIL, IN THE TREATMENT OF LOWER URINARY TRACT SYMPTOMS DUE TO BENIGN PROSTATIC HYPERPLASIA

Benign prostatic hyperplasia (BPH) is a clinical entity defined by urinary symptoms caused by increased stromal and epithelial cells in the transitional zone surrounding the urethra, resulting in urethral pathway narrowing and bladder outlet obstruction (BOO), as well as secondary bladder changes that promote over- or under detrusor muscle activity, resulting in lower urinary tract symptoms (LUTS).[1] Mild LUTS were present in 60% of men with symptomatic BPH at the time of diagnosis. BPH and LUTS are expected to become more prevalent as individuals live longer and use screening and diagnostic technology more frequently.[3] The symptoms of LUTS linked to BPH, such as urgency, nocturia, diminished and intermittent force of stream, and the feeling that the bladder is not emptying, are nonspecific. However, BOO is the most frequent cause of LUTS and can happen in two ways. First, an excess of prostate tissue blocks urine flow. Second, the number and tone of prostatic smooth muscle cells increase, making the urethra more resistant to urine flow.[2]